Aristeia Capital’s TriSalus Life Sciences Warrant TLSIW Stock Holding History

Aristeia Capital’s Portfolio TLSIW Stock Details TLSIW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$35.8K	Buy	28,616 +550	+2%	+$741	﹤0.01%	616
2025 Q4	$42.7K	Buy	+28,066	New	+$35.8K	﹤0.01%	525
2024 Q2	–	Sell	-53,561	Closed	-$58.9K	–	386
2024 Q1	$58.9K	Hold	53,561	–	–	﹤0.01%	200
2023 Q4	$57.3K	Buy	+53,561	New	+$23.7K	﹤0.01%	114
2022 Q1	–	Sell	-384,495	Closed	-$205K	–	740
2021 Q4	$205K	Hold	384,495	–	–	﹤0.01%	529
2021 Q3	$321K	Hold	384,495	–	–	0.01%	434
2021 Q2	$392K	Hold	384,495	–	–	0.01%	410
2021 Q1	$423K	Buy	+384,495	New	+$694K	0.01%	406

Other funds holding TLSIW

Cerity Partners New York $70.8B AUM 21.68% 1-Year Est. Return

Vestcor Inc Fredericton, New Brunswick, Canada $3.63B AUM 21.49% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

FBCM

Fort Baker Capital Management Larkspur, California $1.27B AUM 25.46% 1-Year Est. Return

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return

Rockefeller Capital Management New York $56.4B AUM 24.96% 1-Year Est. Return

Aristeia Capital's TLSIW Position: Q1 2026 in Review

Aristeia Capital increased its TriSalus Life Sciences Warrant (TLSIW) stake by 2% in Q1 2026, buying an estimated $741 and bringing the position to 28,616 shares worth $35.8K. The position accounts for ﹤0.01% of the portfolio, ranked #616.

Aristeia Capital first reported a position in TLSIW in Q1 2021 and has held it in 8 quarters since. The position peaked at $423K in Q1 2021. 7 funds tracked by Wall St. Rank hold TLSIW as of Q1 2026.

Aristeia Capital held 28,616 shares of TriSalus Life Sciences Warrant worth $35.8K as of Q1 2026.
Aristeia Capital bought 550 TriSalus Life Sciences Warrant shares in Q1 2026, an estimated $741.
TriSalus Life Sciences Warrant made up ﹤0.01% of Aristeia Capital's portfolio in Q1 2026, its #616 holding.
Aristeia Capital first reported a position in TriSalus Life Sciences Warrant in Q1 2021 and has held it in 8 quarters since.
Aristeia Capital's TriSalus Life Sciences Warrant position peaked at $423K in Q1 2021.
7 funds tracked by Wall St. Rank held TriSalus Life Sciences Warrant as of Q1 2026.

Based on Aristeia Capital's 13F filing for Q1 2026, filed 15 May 2026.